| Autor: |
Moro-Alvarez MJ; Unidad de Metabolismo Mineral y Oseo, Servicio de Medicina Interna, Hospital Central de la Cruz Roja, Madrid, España., Cabrera JA |
| Jazyk: |
Spanish; Castilian |
| Zdroj: |
Revista clinica espanola [Rev Clin Esp] 2010 Jul-Aug; Vol. 210 (7), pp. 342-9. Date of Electronic Publication: 2010 May 23. |
| DOI: |
10.1016/j.rce.2009.11.023 |
| Abstrakt: |
Osteoporosis in men continues to be underdiagnosed and undertreated. Its presence makes it necessary to rule out predisposing conditions and diseases. General prevention measures should be recommended and when necessary also supplementation with 1200mg/day of calcium and at least 800IU/day of vitamin D. Bisphosphonates, specifically alendronate (ALN) and risedronate (RSN), are the treatment of choice in men with osteoporosis. In severe cases with high risk of fracture and in patients with therapeutic failure with the bisphosphonates or who do not tolerate these drugs, the use of teriparatide may be recommended. The evidence available suggests that anti-fracture efficacy of treatment with ALN, RSN and teriparatide is similar in both genders. Androgens are only justified if there is clinical hypogonadism. Even in this case, bisphosphonates or teriparatide should probably be associated if the risk of fracture is very high in spite of androgen replacement. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
